Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

Seungyoun Jung, Naomi Allen, Alan A Arslan, Laura Baglietto, Aurelio Barricarte, Louise A Brinton, Brian L Egleston, Roni T Falk, Renée T Fortner, Kathy J Helzlsouer, Yutang Gao, Annika Idahl, Rudolph Kaaks, Vittorio Krogh, Melissa A Merritt, Eva Lundin, N Charlotte Onland-Moret, Sabina Rinaldi, Helena Schock, Xiao-Ou ShuPatrick M Sluss, Paul N Staats, Carlotta Sacerdote, Ruth C Travis, Anne Tjønneland, Antonia Trichopoulou, Shelley S Tworoger, Kala Visvanathan, Elisabete Weiderpass, Anne Zeleniuch-Jacquotte, Joanne F Dorgan

Research output: Contribution to journalArticle

Abstract

Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.

Original languageEnglish
Pages (from-to)262-270
Number of pages9
JournalInternational Journal of Cancer
Volume142
Issue number2
DOIs
Publication statusPublished - Jan 15 2018

Fingerprint

Ovarian Neoplasms
Hormones
Odds Ratio
Confidence Intervals
Oral Contraceptives
Case-Control Studies
Epidemiologic Studies
Neoplasms
Logistic Models
Enzyme-Linked Immunosorbent Assay
Growth

Keywords

  • Adenocarcinoma, Clear Cell/blood
  • Adenocarcinoma, Mucinous/blood
  • Adult
  • Anti-Mullerian Hormone/blood
  • Biomarkers/blood
  • Case-Control Studies
  • Cohort Studies
  • Cystadenocarcinoma, Serous/blood
  • Endometrial Neoplasms/blood
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Ovarian Neoplasms/blood
  • Premenopause
  • Prognosis
  • Young Adult

Cite this

Jung, S., Allen, N., Arslan, A. A., Baglietto, L., Barricarte, A., Brinton, L. A., ... Dorgan, J. F. (2018). Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. International Journal of Cancer, 142(2), 262-270. https://doi.org/10.1002/ijc.31058

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. / Jung, Seungyoun; Allen, Naomi; Arslan, Alan A; Baglietto, Laura; Barricarte, Aurelio; Brinton, Louise A; Egleston, Brian L; Falk, Roni T; Fortner, Renée T; Helzlsouer, Kathy J; Gao, Yutang; Idahl, Annika; Kaaks, Rudolph; Krogh, Vittorio; Merritt, Melissa A; Lundin, Eva; Onland-Moret, N Charlotte; Rinaldi, Sabina; Schock, Helena; Shu, Xiao-Ou; Sluss, Patrick M; Staats, Paul N; Sacerdote, Carlotta; Travis, Ruth C; Tjønneland, Anne; Trichopoulou, Antonia; Tworoger, Shelley S; Visvanathan, Kala; Weiderpass, Elisabete; Zeleniuch-Jacquotte, Anne; Dorgan, Joanne F.

In: International Journal of Cancer, Vol. 142, No. 2, 15.01.2018, p. 262-270.

Research output: Contribution to journalArticle

Jung, S, Allen, N, Arslan, AA, Baglietto, L, Barricarte, A, Brinton, LA, Egleston, BL, Falk, RT, Fortner, RT, Helzlsouer, KJ, Gao, Y, Idahl, A, Kaaks, R, Krogh, V, Merritt, MA, Lundin, E, Onland-Moret, NC, Rinaldi, S, Schock, H, Shu, X-O, Sluss, PM, Staats, PN, Sacerdote, C, Travis, RC, Tjønneland, A, Trichopoulou, A, Tworoger, SS, Visvanathan, K, Weiderpass, E, Zeleniuch-Jacquotte, A & Dorgan, JF 2018, 'Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts', International Journal of Cancer, vol. 142, no. 2, pp. 262-270. https://doi.org/10.1002/ijc.31058
Jung S, Allen N, Arslan AA, Baglietto L, Barricarte A, Brinton LA et al. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. International Journal of Cancer. 2018 Jan 15;142(2):262-270. https://doi.org/10.1002/ijc.31058
Jung, Seungyoun ; Allen, Naomi ; Arslan, Alan A ; Baglietto, Laura ; Barricarte, Aurelio ; Brinton, Louise A ; Egleston, Brian L ; Falk, Roni T ; Fortner, Renée T ; Helzlsouer, Kathy J ; Gao, Yutang ; Idahl, Annika ; Kaaks, Rudolph ; Krogh, Vittorio ; Merritt, Melissa A ; Lundin, Eva ; Onland-Moret, N Charlotte ; Rinaldi, Sabina ; Schock, Helena ; Shu, Xiao-Ou ; Sluss, Patrick M ; Staats, Paul N ; Sacerdote, Carlotta ; Travis, Ruth C ; Tjønneland, Anne ; Trichopoulou, Antonia ; Tworoger, Shelley S ; Visvanathan, Kala ; Weiderpass, Elisabete ; Zeleniuch-Jacquotte, Anne ; Dorgan, Joanne F. / Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. In: International Journal of Cancer. 2018 ; Vol. 142, No. 2. pp. 262-270.
@article{d650c8d0ebd342e5971dbb58fe374555,
title = "Anti-M{\"u}llerian hormone and risk of ovarian cancer in nine cohorts",
abstract = "Animal and experimental data suggest that anti-M{\"u}llerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95{\%} confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95{\%} CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.",
keywords = "Adenocarcinoma, Clear Cell/blood, Adenocarcinoma, Mucinous/blood, Adult, Anti-Mullerian Hormone/blood, Biomarkers/blood, Case-Control Studies, Cohort Studies, Cystadenocarcinoma, Serous/blood, Endometrial Neoplasms/blood, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Grading, Neoplasm Staging, Ovarian Neoplasms/blood, Premenopause, Prognosis, Young Adult",
author = "Seungyoun Jung and Naomi Allen and Arslan, {Alan A} and Laura Baglietto and Aurelio Barricarte and Brinton, {Louise A} and Egleston, {Brian L} and Falk, {Roni T} and Fortner, {Ren{\'e}e T} and Helzlsouer, {Kathy J} and Yutang Gao and Annika Idahl and Rudolph Kaaks and Vittorio Krogh and Merritt, {Melissa A} and Eva Lundin and Onland-Moret, {N Charlotte} and Sabina Rinaldi and Helena Schock and Xiao-Ou Shu and Sluss, {Patrick M} and Staats, {Paul N} and Carlotta Sacerdote and Travis, {Ruth C} and Anne Tj{\o}nneland and Antonia Trichopoulou and Tworoger, {Shelley S} and Kala Visvanathan and Elisabete Weiderpass and Anne Zeleniuch-Jacquotte and Dorgan, {Joanne F}",
note = "{\circledC} 2017 UICC.",
year = "2018",
month = "1",
day = "15",
doi = "10.1002/ijc.31058",
language = "English",
volume = "142",
pages = "262--270",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

AU - Jung, Seungyoun

AU - Allen, Naomi

AU - Arslan, Alan A

AU - Baglietto, Laura

AU - Barricarte, Aurelio

AU - Brinton, Louise A

AU - Egleston, Brian L

AU - Falk, Roni T

AU - Fortner, Renée T

AU - Helzlsouer, Kathy J

AU - Gao, Yutang

AU - Idahl, Annika

AU - Kaaks, Rudolph

AU - Krogh, Vittorio

AU - Merritt, Melissa A

AU - Lundin, Eva

AU - Onland-Moret, N Charlotte

AU - Rinaldi, Sabina

AU - Schock, Helena

AU - Shu, Xiao-Ou

AU - Sluss, Patrick M

AU - Staats, Paul N

AU - Sacerdote, Carlotta

AU - Travis, Ruth C

AU - Tjønneland, Anne

AU - Trichopoulou, Antonia

AU - Tworoger, Shelley S

AU - Visvanathan, Kala

AU - Weiderpass, Elisabete

AU - Zeleniuch-Jacquotte, Anne

AU - Dorgan, Joanne F

N1 - © 2017 UICC.

PY - 2018/1/15

Y1 - 2018/1/15

N2 - Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.

AB - Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.

KW - Adenocarcinoma, Clear Cell/blood

KW - Adenocarcinoma, Mucinous/blood

KW - Adult

KW - Anti-Mullerian Hormone/blood

KW - Biomarkers/blood

KW - Case-Control Studies

KW - Cohort Studies

KW - Cystadenocarcinoma, Serous/blood

KW - Endometrial Neoplasms/blood

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Ovarian Neoplasms/blood

KW - Premenopause

KW - Prognosis

KW - Young Adult

U2 - 10.1002/ijc.31058

DO - 10.1002/ijc.31058

M3 - Article

C2 - 28921520

VL - 142

SP - 262

EP - 270

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -